-
FDA Narrows Use of PD-1 Drugs in GI Cancers
FDA
The FDA has restricted Merck’s Keytruda and BMS’s Opdivo for use only in PD-L1-positive gastric, GEJ, and esophageal cancers, citing limited benefit in PD-L1-negative patients based on recent trial data.
-
PD-(L)1 Resistance Hope
PD-1
Explore how LRRC15+ CAFs contribute to PD-1 resistance, the role of LRRC15 in tumor immunity, and emerging therapies targeting LRRC15 and PD-1 to improve cancer immunotherapy outcomes.
积石山|
高阳县|
丽江市|
大安市|
江都市|
忻州市|
乌兰察布市|
西平县|
来安县|
游戏|
武胜县|
靖安县|
延庆县|
阳朔县|
文登市|
南通市|
察隅县|
瑞昌市|
和政县|
宜丰县|
涿州市|
夏邑县|
若羌县|
上高县|
宕昌县|
阳信县|
塘沽区|
湘潭县|
鄱阳县|
大港区|
南靖县|
景洪市|
张北县|
安庆市|
邵东县|
息烽县|
阿克陶县|
建瓯市|
太康县|
米易县|
安多县|